Mitigating Risks Critical To Ending Polio Globally

PLOS Medicine: Sailing in Uncharted Waters: Carefully Navigating the Polio Endgame
Elizabeth Miller, consultant epidemiologist in the Immunisation, Hepatitis and Blood Safety Department at Public Health England, and T. Jacob John, consultant pediatrician at the Child Health Foundation, discuss the risks and benefits of the use of oral poliovirus vaccines (OPV) and inactivated polio vaccine (IPV). They conclude, “Until all risks of OPV cessation are understood and mitigated, continued IPV coverage will be necessary” (10/4).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.